Evidence map›Paper›PMID 34162631›Full record

ArticleBMJ open2021

Tailored mHealth intervention for improving treatment adherence for people living with HIV in Iran (HamRaah): protocol for a feasibility study and randomised pilot trial with a nested realist evaluation.

Vira Ameli, Jessica Haberer, Lora Sabin, Franziska Meinck, Jane Barlow, Leila Taj, Minoo Mohraz

Abstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vira AmeliSocial Policy and Intervention, University of Oxford, Oxford, Oxfordshire, UK vira.ameli@spi.ox.ac.uk.ORCID 0000-0002-2403-442X
Jessica HabererMedicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Lora SabinGlobal Health, Boston University School of Public Health, Boston, Massachusetts, USA.
Franziska MeinckSchool of Social and Political Science, The University of Edinburgh, Edinburgh, UK.
Jane BarlowDepartment of Social Policy, University of Oxford, Oxford, Oxfordshire, UK.
Leila TajIranian Research Centre for HIV/AIDS, Tehran University of Medical Sciences, Tehran, Iran (the Islamic Republic of).
Minoo MohrazIranian Research Centre for HIV/AIDS, Tehran University of Medical Sciences, Tehran, Iran (the Islamic Republic of).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMiddle East and North Africa (MENA) has a rising rate of new HIV infections and AIDS-related mortality. Consistent adherence to antiretroviral therapy (ART) leads to viral suppression, preventing HIV transmission and treatment failure. mHealth interventions can improve ART adherence by providing tailored support and directing patients to existing healthcare services. HamRaah (Persian for 'together-in-path') is the first mHealth-based intervention in a MENA country and is designed to improve adherence through two-way mobile messaging for people recently diagnosed with HIV in Tehran, Iran. The objectives of this pilot randomised controlled trial (RCT) are to examine the feasibility, acceptability and preliminary effectiveness of HamRaah, and to develop an explanatory theory for any observed effects through a nested realist evaluation.

methodsA feasibility study and two-arm RCT of HamRaah, with an embedded realist evaluation will be conducted. Participants will be randomised 1:1 to HamRaah or routine care for a 6-month intervention. The initial effectiveness of HamRaah will be assessed through the primary outcome of self-reported ART adherence and several secondary outcomes: retention in care, CD4 count and viral suppression. A theory-driven realist evaluation framework will be used to develop an explanatory theory regarding what works, for whom, how and in what context. ETHICS AND DISSEMINATION: The study received ethical clearance from Tehran University of Medical Sciences Ethics Committee and Oxford Tropical Research Ethics Committee People living with HIV in Tehran and key country stakeholders in HIV policy and programming have been involved in the development of HamRaah and this pilot trial. Participants will provide informed consent prior to study enrolment. The results will be disseminated to all stakeholders and presented in peer-reviewed journal publications and conferences. TRIAL REGISTRATION NUMBER: IRCT20100601004076N23; Pre-results.

Indexed as

HIV InfectionsTelemedicineAfrica, NorthernFeasibility StudiesHumansIranMedication AdherenceMiddle EastPilot ProjectsRandomized Controlled Trials as TopicTreatment Adherence and ComplianceHIV & AIDSpublic healthtelemedicine

Identifiers

PMID34162631
PMCPMC8231034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.